A Phase 1 interventional study of SA1211 injection and SA1211 injection placebo in Chronic Hepatitis B, sponsored by Suzhou Siran Biotechnology Co.,Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-10.
Sponsored by Suzhou Siran Biotechnology Co.,Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 378 studies in Hepatitis B, Chronic with a site in China — 91 open to participants now, 112 under way, 7 of them phase 3. Hepatitis B, Chronic · China.
Among the 378 studies in Hepatitis B, Chronic with a site in China, this one is the 190th largest by planned enrollment of the 274 interventional ones that give a count, is one of 24 that started in 2025, is one of 51 in phase 1, reaches primary completion later than 58 of the 111 other live ones, and was the 340th registered.
899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.
Browse Hepatitis B, Chronic studies →91 of the 378 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:
Jiyan Liu · Sites in China
Ages 18–65
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Fujian Akeylink Biotechnology Co., Ltd. · Sites in China
Ages 35–65
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Fujian Akeylink Biotechnology Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
378 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 63 · Phase 2 85 · Phase 3 27 · Phase 4 73
First in 2000; this study’s year is marked. 24 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 100 across 660 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 120 across the 274 interventional studies, 500 across the 101 observational. Of the 152 that completed or were terminated, 30 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
168 of 378 have an industry lead sponsor. The 10 most frequent:
Suzhou Siran Biotechnology Co.,Ltd. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Suzhou Siran Biotechnology Co.,Ltd. has 1 study filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
41 of the studies in Hepatitis B, Chronic with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07090759Phase 3Fujian Akeylink Biotechnology Co., Ltd.To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment | 2026-12-01 |
| NCT07246889Phase 3Ausper Biopharma Co., Ltd.Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) | 2026-12-18 |
| NCT07307586Phase 3Zhigang RenA Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B | 2026-12-31 |
| NCT07203118Phase 3Xi'an Xintong Pharmaceutical Research Co.,Ltd.A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B | 2027-06-30 |
| NCT02863757Humanity and Health Research CentreFollow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease | 2026-12 |
Add all 41 to your calendar (.ics) → With an account.
Among the 378 studies in Hepatitis B, Chronic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of SA1211 Injection in healthy volunteers (Part A) and participants with chronic hepatitis B (CHB, Part B), and assess its preliminary efficacy in participants with chronic hepatitis B (CHB). The main questions it aims to answer are:
What are the safety, tolerability, immunogenicity and PK characteristics of a single subcutaneous injection of SA1211 Injection in healthy volunteers (Part A)? What are the safety, tolerability, immunogenicity and PK characteristics of multiple subcutaneous injections of SA1211 Injection in participants with CHB (Part B)? What is the preliminary efficacy of SA1211 Injection in participants with CHB (Part B)?
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female participants.
(BMI) meets the following requirements.
During the screening period, the results of the following examinations are either normal or abnormal but not clinically insignificant:
- Clinical laboratory tests: complete blood count, blood biochemistry, coagulation function, urine routine. Thyroid function test. 12-lead (ECG). Abdominal ultrasound. Posteroanterior chest X-ray.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SA1211 injection · Drug: SA1211 injection placebo
Drug: SA1211 injection · Drug: SA1211 injection placebo
subcutaneous injection
subcutaneous injection
Number of participants with AEs, SAEs and abnormal laboratory testings
AEs: Adverse Events. SAEs: Serious Adverse Events.
Time frame: Approximate 24 weeks
Cmax: maximum concentration
Time frame: Pre-dose, multiple time-points post dose until 48 hours
Tmax
Tmax: Time to Maximum Concentration
Time frame: Pre-dose, multiple time-points post dose until 48 hours
AUC0-t
AUC0-t: Area Under the Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration
Time frame: Pre-dose, multiple time-points post dose until 48 hours
AUC0-inf
AUC0-inf: Area Under the Concentration-Time Curve from Time Zero to Infinity
Time frame: Pre-dose, multiple time-points post dose until 48 hours
t1/2
t1/2: Half-life
Time frame: Pre-dose, multiple time-points post dose until 48 hours
λz
λz: Terminal Elimination Rate Constant
Time frame: Pre-dose, multiple time-points post dose until 48 hours
Vd/F
Vd/F: Volume of Distribution over Bioavailability
Time frame: Pre-dose, multiple time-points post dose until 48 hours
CL/F
CL/F: Clearance over Bioavailability
Time frame: Pre-dose, multiple time-points post dose until 48 hours
Css (Steady-State Concentration)
Time frame: Pre-dose, multiple time-points post dose until 48 hours
DF (Degree of Fluctuation)
Time frame: Pre-dose, multiple time-points post dose until 48 hours
The number of participants with chronic hepatitis B (CHB) who achieved hepatitis B surface antigen (HBsAg) clearance
Time frame: Approximate 24 weeks
Maximum HBsAg Decline in CHB Participants Within 24 Weeks (log10)
Time frame: Approximate 24 weeks
The number of CHB Participants with HBsAg Seroconversion at each assessment time Point within 24 weeks
Time frame: Approximate 24 weeks
The number of CHB participants who achieved HBeAg seronegativity at each assessment time point within 24 weeks
Time frame: Approximate 24 weeks
The number of participants with immunogenicity (i.e., anti-drug antibodies [ADAs])
Time frame: Approximate 24 weeks
The change in QTcF relative to baseline and the change relative to placebo
Apply for healthy participants
Time frame: Approximate 24 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Mar 2027, 16 months after the start.
Of 74 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 16 months is close to that.
Counting every sponsor, half of 82 studies reached it within 16 months; a quarter within 6 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Suzhou Siran Biotechnology Co.,Ltd.